Cargando…

Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial

SIMPLE SUMMARY: There is no valid consensus regarding follow-up for pancreatic cancer in terms of recommended investigations in routine practice. By analogy with other pathologies, cross-sectional imaging is often performed every 3 months. In addition, the low number of available chemotherapy regime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egea, Julie, Salleron, Julia, Gourgou, Sophie, Ayav, Ahmet, Laurent, Valérie, Juzyna, Béata, Harlé, Alexandre, Conroy, Thierry, Lambert, Aurélien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599967/ https://www.ncbi.nlm.nih.gov/pubmed/36291851 http://dx.doi.org/10.3390/cancers14205068

Ejemplares similares

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial
por: Lambert, Aurélien, et al.
Publicado: (2017)

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial
por: Legrand, Théo, et al.
Publicado: (2022)

Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17
por: Cuer, B., et al.
Publicado: (2020)

When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials
por: Touraine, Célia, et al.
Publicado: (2023)

The prodigal son
por: Britten, Benjamin, 1913-1976
Publicado: (1990)

Cilia - the prodigal organelle
por: Beales, Phil, et al.
Publicado: (2012)

Les prodiges : piéce en deux parties /
por: Vauthier, Jean
Publicado: (1958)

The return of the prodigal Goldstone boson
por: Kapusta, Joseph I., et al.
Publicado: (1995)

Prodigal: prokaryotic gene recognition and translation initiation site identification
por: Hyatt, Doug, et al.
Publicado: (2010)

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
por: de Rauglaudre, Bernadette, et al.
Publicado: (2022)

The prodigal tongue: the love-hate relationship between British and American English
por: Murphy, Lynne
Publicado: (2018)

Growth rate evolution in improved environments under Prodigal Son dynamics
por: Collins, Sinéad
Publicado: (2016)

The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib
por: Conroy, Guillaume, et al.
Publicado: (2017)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma
por: Serre, Delphine, et al.
Publicado: (2018)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

Comment on “Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery: A Five-Year Follow-Up of the RAPIDO Trial”: The RAPIDO Trial Does Not Achieve Its Primary Endpoint
por: Riou, Olivier, et al.
Publicado: (2023)

Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma
por: Harlé, Alexandre, et al.
Publicado: (2016)

Somatic substitution signature as an innovative tool in lung cancer diagnosis
por: Busca, Stéphane, et al.
Publicado: (2019)

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
por: Aparicio, Thomas, et al.
Publicado: (2020)

ProDiGe: Prioritization Of Disease Genes with multitask machine learning from positive and unlabeled examples
por: Mordelet, Fantine, et al.
Publicado: (2011)

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
por: Aparicio, T, et al.
Publicado: (2018)

Signes et prodiges: il y a plus d’une façon d’écouter une histoire
por: Tudiver, Sari Lubitsch
Publicado: (2022)

Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management
por: Sommariva, Antonio, et al.
Publicado: (2022)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers
por: Gilson, Pauline, et al.
Publicado: (2021)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
por: Lambert, Aurélien, et al.
Publicado: (2021)

Advanced nonmetastatic hepatocellular carcinoma: curative surgery may be an option
por: Leclerc, Julie, et al.
Publicado: (2022)

Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials
por: Barbieri, Antoine, et al.
Publicado: (2017)

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03
por: Fayette, Jerome, et al.
Publicado: (2017)

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
por: Modesto, Anouchka, et al.
Publicado: (2023)

Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol
por: Boilève, Alice, et al.
Publicado: (2020)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
por: Renaud, Myriam, et al.
Publicado: (2022)

Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets
por: Chen, Shuhui, et al.
Publicado: (2016)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
por: Hahn, Sarah, et al.
Publicado: (2017)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Hyperoxia toxicity in septic shock patients according to the Sepsis-3 criteria: a post hoc analysis of the HYPER2S trial
por: Demiselle, Julien, et al.
Publicado: (2018)

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study
por: Gaiffe, E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a16c84l4djl8t4jtr24qsehh92